Helio Genomics在2025年圣地亚哥消化疾病周上展示了三项关于通过血液检测早期发现癌症的摘要-动脉网

Helio Genomics Presents Three Abstracts on Early Cancer Detection with a Bloodased Test at the 2025 Digestive Disease Week in San Diego

CISION 等信源发布 2025-05-02 00:02



可切换为仅中文







IRVINE, Calif.

尔湾，加利福尼亚州

，

May 1, 2025

2025年5月1日

/PRNewswire/ -- Helio Genomics ('Helio' or 'the Company'), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced that they will be presenting three different abstracts at the 2025 Digestive Disease Week Conference, held at the .

/PRNewswire/ -- Helio Genomics（“Helio”或“公司”），一家专注于癌症检测诊断技术和测试开发的AI驱动医疗公司，今天宣布他们将在2025年消化疾病周会议上展示三项不同的摘要研究。

San Diego

圣地亚哥

Convention Center in

会展中心位于

San Diego, CA

加利福尼亚州圣地亚哥

from

从

May 4-6, 2025

2025年5月4日至6日

。

Most notably, it will be the first showcase of a simulated longitudinal study comparing a multi-analyte blood-based test (HelioLiver) against ultrasound for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.

最值得注意的是，这将是首个展示模拟纵向研究的平台，该研究比较了基于血液的多分析物测试（HelioLiver）与超声波在肝硬化患者中检测肝细胞癌（HCC）的效果。

Poster Presentations (

海报展示 (

Tuesday May 6, 2025

2025年5月6日，星期二

，

12:30-1:30pm PT

中午12:30至下午1:30（太平洋时间）

Poster #1:

海报 #1:

Simulation of Longitudinal Ultrasound versus a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma in Patients with Cirrhosis

模拟纵向超声与多分析物血液检测在肝硬化患者中检测肝细胞癌的比较

(4254801)

, presented by Dr.

，由博士展示。

Amit Singal

阿米特·辛格尔

, MD, MS, FAASLD -

，医学博士，硕士，FAASLD -

Professor of Medicine, UT Southwestern Medical Center

德克萨斯大学西南医学中心医学教授

Poster #2:

海报 #2:

Cell-Free DNA Methylation Biomarkers for Evaluating Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma

无细胞DNA甲基化生物标志物在评估肝细胞癌患者的预后和治疗反应中的应用

(4254671)

, presented by

，由以下内容呈现

Shivani Mahajan

施瓦尼·马哈詹

, Ph.D – Head of Computational Science at Helio Genomics.

博士 – Helio Genomics计算科学部门负责人。

Poster #3:

海报 #3:

CLiMB: A Prospective, Blinded, Multicenter U.S. Based Study Evaluating a Multi-Analyte Blood-Based Test for Detecting Hepatocellular Carcinoma (HCC) in Patients with Liver Cirrhosis

CLiMB：一项前瞻性、盲法、多中心的美国研究，评估基于血液的多分析物检测方法在肝硬化患者中检测肝细胞癌（HCC）的效果

(4253880)

, presented by Dr.

，由博士展示。

Richard Van Etten

理查德·范·艾滕

, MD, PhD – Director of the Chao Family Comprehensive Cancer Center at UCI and Chief Medical Advisor at Helio Genomics

医学博士、哲学博士——加州大学欧文分校查奥家族综合癌症中心主住及Helio Genomics首席医学顾问

Copies of the poster presentations will be available in the 'Past Events' section on Helio's website at

海报展示的副本将在 Helio 网站的“过去活动”部分提供。

https://heliogenomics.com/news-and-events

after the conference has concluded.

会议结束后。

About Helio Genomics

关于Helio基因组学

Helio Genomics is a commercial stage, AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection. HelioLiver is a multi-analyte blood test that evaluates cell free DNA (cfDNA) methylation patterns, serum protein markers, and demographic information for the detection of hepatocellular carcinoma (HCC).

Helio Genomics是一家商业阶段、以人工智能为驱动的医疗保健公司，专注于癌症检测的诊断技术和测试开发。HelioLiver是一种多指标血液测试，通过评估游离DNA（cfDNA）甲基化模式、血清蛋白标志物和人口统计信息来检测肝细胞癌（HCC）。

For more information, please visit our website at .

如需更多信息，请访问我们的网站。

www.heliogenomics.com

或

www.linkedin.com/company/heliogenomics

; information that may be important to investors will be routinely posted in both locations.

对投资者来说重要的信息将定期发布在两个位置。

SOURCE Helio Genomics

来源：Helio Genomics

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗